Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis

NCT02376972 is registered in ClinicalTrials.gov with Alfasigma S.p.A. as lead sponsor.

NCT NCT02376972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02376972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis
Lead sponsor
Alfasigma S.p.A.
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2015
Completion date
February 29, 2016
Enrollment
392 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial vaginosis